A system for preserving a lung is close-to-air. Liquid can flow in and out of a ventilation chamber. Cannulations or other connections to the trachea, the left atrium, and the pulmonary artery of the lung are located at the bottom of the chamber. A lung is connected from the bottom of the chamber in an upside-down position, opposite direction as normal human anatomy. The lung floats in the liquid, approximately at the center of the chamber. A diaphragm or other movable plug located at the top of the chamber changes the lung volume. The chamber with the diaphragm can be discarded after use.
Embodiments of the disclosure include methods and compositions for improving heart function, including reducing the risk of arrhythmia in an individual in need thereof. In particular embodiments, an individual with a need for improved heart function and/or reduced risk of arrhythmia is provided an effective amount of a shRNA molecule that targets the Sav1 gene.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
N,N-disubstituted aminocarbonyl compounds and their use as integrin agonists for enhancing the binding of integrin-expressing cells to integrin-binding ligands or receptors.
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
C07C 237/24 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
C07C 271/24 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
4.
CENTRIFUGAL LVAD WITH WIRELESS POWER TRANSFER AND ANTITHROMBOTIC SLIC COATING
An exemplary left ventricular assist device (LVAD) and method that employs design and material designs to reduce the thrombosis risk of LVAD implant in a patient. One feature of the design includes a stented inlet member for the device that can reduce or fully eliminate a flow stasis that can trigger blood protein adsorption that can lead to chain reactions that then result in thrombosis. Other features of the design include (i) a flexible rotor and/or pump housing that can reduce blood damage, (ii) hydrophilic slippery coatings at high sheer components, such as the rotor to further reduce protein adsorption and thus thrombosis risk, (iii) magnetic-based drive and bearing components that can improve the hemocompatibility of the blood pump, and (iv) advanced controls and charging.
A61M 60/178 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable in, on, or around the heart drawing blood from a ventricle and returning the blood to the arterial system via a cannula external to the ventricle, e.g. left or right ventricular assist devices
A61M 60/216 - Non-positive displacement blood pumps including a rotating member acting on the blood, e.g. impeller
A61M 60/861 - Connections or anchorings for connecting or anchoring pumps or pumping devices to parts of the patient’s body
N,N-disubstituted arylamine compounds and to their use as integrin agonists for enhancing binding of integrin-expressing cells to integrin-binding ligands or receptors.
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
C07D 213/89 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
C07D 277/56 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Disclosed herein, in some aspects, are endotracheal stimulation platforms, systems, and methods of their use for pacing the phrenic nerves, right and/or left phrenic nerves, of a subject. In some embodiments, one or more pairs of electrodes are provided through an ET tube to contact a portion of a tracheal wall, or trachea, so as to enable phrenic nerve pacing. In some cases, the one or more pairs of electrodes are configured to send electrical pulses that stimulate the phrenic nerve, thereby helping promote contraction and relaxation of the diaphragm muscle.
The invention relates in one aspect to compounds, pharmaceutical compositions thereof, and methods using the same for selectively activating either all or a single isoform of Akt. Isoform selective-targeting is necessary for avoiding pathologies driven by concomitantly activated Akt1, Akt2 and/or Akt3.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
Embodiments of the disclosure include methods and compositions for the renewal of cardiomyocytes by targeting the Hippo pathway. In particular embodiments, an individual with a need for cardiomyocyte renewal is provided an effective amount of a shRNA molecule that targets the Sav1 gene. Particular shRNA sequences are disclosed.
Provided is a modified Yes-associated protein (YAP) in which the serine residues of the LATS1/2 phosphorylation sites and a serine residue in the region of YAP that binds to TEAD are substituted with alanines. Also provided are nucleic acids encoding the modified YAP, vectors comprising the nucleic acids, and compositions comprising the modified YAP, nucleic acids encoding the modified YAP, or vectors comprising the nucleic acids. Further provided are methods of regenerating cardiomyocytes and of treating cardiac conditions.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 9/00 - Drugs for disorders of the cardiovascular system
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
One aspect of the invention provides a trocar including: a central cylinder defining a central channel and having a distal end adapted and configured for insertion within a subject; one or more gas outlets located within the central cylinder proximate to the distal end of the trocar; and one or more liquid outlets located within the central cylinder on a proximal side of the one or more gas outlets. The one or more liquid outlets are adapted and configured to dispense a liquid when an endoscope is withdrawn from a fully extended position within the central channel of the trocar to a position proximate to the one or more liquid outlets. Distal advancement of the endoscope to a position adjacent to the one or more gas outlets removes liquid from a distal end of the endoscope.
A61B 1/12 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with cooling or rinsing arrangements
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
A61B 1/015 - Control of fluid supply or evacuation
Embodiments of the disclosure include methods for generating skeletal muscle by targeting the Hippo pathway. In particular embodiments, an individual with a need for skeletal muscle generation is provided an effective amount of a shRNA molecule that targets the SAV1 gene. Particular shRNA sequences are disclosed.
A catheter deploys a flexible electrode that is at least partially made of preformed hydrogel to a target location in order to provide radiofrequency catheter ablation. The catheter stores the flexible electrode, which can be deployed and retracted. The preformed hydrogel is conductive and thus can provide an interface between a conductive metal wire and a target cardiac tissue. Electric energy is applied to the portions of the cardiac tissue target tissue that are the genesis of the errant and abnormal heartbeats via the flexible electrode. The electric energy may create lesions with lower risks of steam pops and tissue perforation.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
14.
MINIMALLY-INVASIVE SURGICAL CUTTING DEVICES FOR CUTTING FIBROTIC TISSUE
A surgical cutting device for performing a minimally-invasive surgical procedure and which includes an external hub including a housing and a cutter actuator housed within the housing, wherein the cutter actuator, a catheter including a first end coupled to the external hub, a second end opposite the first end, and an internal passage, a cutting tool coupled to the second end of the catheter and including a cutting element moveable relative to the second end of the catheter by the cutter actuator, and a motion transfer assembly extending through the internal passage of the catheter from the cutter actuator to the cutting tool, wherein the motion transfer assembly is configured to transfer motion from the cutter actuator to the cutting element of the cutting tool in response to the activation of the cutter actuator.
N,N-disubstituted aminocarbonyl compounds and their use as integrin agonists for enhancing the binding of integrin-expressing cells to integrin-binding ligands or receptors.
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 295/15 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 241/08 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 9/00 - Medicinal preparations characterised by special physical form
N,N-disubstituted arylamine compounds and to their use as integrin agonists for enhancing binding of integrin-expressing cells to integrin-binding ligands or receptors.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 263/48 - Nitrogen atoms not forming part of a nitro radical
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 277/42 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
C07D 279/08 - 1,3-ThiazinesHydrogenated 1,3-thiazines condensed with carbocyclic rings or ring systems
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 213/89 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
A61P 9/00 - Drugs for disorders of the cardiovascular system
Disclosed herein, in some aspects, are endotracheal stimulation platforms, systems, and methods of their use for pacing the phrenic nerves, right and/or left phrenic nerves, of a subject. In some embodiments, one or more pairs of electrodes are provided through an ET tube to contact a portion of a tracheal wall, or trachea, so as to enable phrenic nerve pacing. In some cases, the one or more pairs of electrodes are configured to send electrical pulses that stimulate the phrenic nerve, thereby helping promote contraction and relaxation of the diaphragm muscle.
The invention relates in one aspect to compounds, pharmaceutical compositions thereof, and methods using the same for selectively activating either all or a single isoform of Akt. Isoform selective-targeting is necessary for avoiding pathologies driven by concomitantly activated Aktl, Akt2 and/or Akt3.
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Medical and surgical services related to the cardiovascular system; Medical and surgical services, namely, diagnosis, treatment, and management of risk factors for cardiac disease, coronary artery disease, heart valve disease, peripheral vascular disease, heart failure, cardiac arrhythmia, venous disorders, congenital heart disease, pulmonary hypertension, diseases of the aorta; Medical and surgical services, namely, cardiac imaging; Medical and surgical services, namely, heart transplantation and mechanically assisted circulation; Medical and surgical services, namely, delivering and implementing progressive care management
21.
USE OF ELECTRICALLY CONDUCTIVE MATERIALS FOR ELECTROPHYSIOLOGY
A method of improving electrical conduction across an impaired region of a tissue (e.g., myocardial tissue), includes applying an electrically conductive wiring carbon nanotube fibers) across the impaired region. The electrically conductive wiring can become associated with non-impaired regions of the tissue on opposite sides of the impaired region by suturing. The method can also be utilized to treat or prevent cardiac arrhythmia in a subject (e.g., ventricular arrhythmia). The electrically conductive wiring includes carbon nanotubes, such as carbon nanotube fibers, Such electrically conductive wiring can be used to transmit electrical signals to a tissue or sense electrical signals from the tissue. Suture threads including carbon nanotubes, such as carbon nanotube fibers, are provided.
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Educational services, namely, arranging and conducting educational conferences in the field of cardiovascular medicine and other medicine; development and dissemination of printed educational materials of others in the field of cardiovascular medicine and other medicine, conducting educational conferences, courses and symposia, and distributing course materials in connection therewith, in the field of cardiovascular medicine; entertainment services in the nature of competitions in the field of athletics, namely, arranging and conducting athletic competitions Providing medical testing services in the field of heart disease research and disease classification; medical and scientific research and medical laboratories in the field of cardiovascular medicine; design and testing for new product development and of new products for others; medical laboratory services; product development and product development consultation; product safety testing; research and development of new products for others; technical medical and scientific research in the field of cardiovascular medicine Medical services; medical testing for diagnostic or treatment purposes; technical medical consultation in the field of cardiovascular medicine
23.
Electrically conductive hydrogels usable as lead extensions, apparatus for delivery of a hydrogel into the vasculature, and methods of treating ventricular arrhythmia with electrically conductive hydrogels injected in the venous system
Board of Regents, The University of Texas System (USA)
Inventor
Cosgriff-Hernandez, Elizabeth
John, Mathews
Post, Allison
Razavi, Mehdi
Chwatko, Malgorzata
Rook, Ashley
Wilems, Thomas
Abstract
A conductive hydrogel precursor solution cures after injection into the vasculature of the myocardium. The vasculature acts as a mold for the hydrogel and allows for a pacing signal to be conducted across the myocardium and not at a single point like traditional pacing leads. The catheter-based delivery can accurately place the hydrogels into the myocardial veins and can fill the venous tributaries. In situ crosslinking of the hydrogel precursor solution is achieved through several mechanisms, such as redox initiation by mixing a reducing reagent and oxidizing agent after injection. Conductivity is achieved by doping in conductive polymers or other conductive elements such as ionic species, metallic nanoparticles, or graphene nanoplatelets. To ensure long-term conductivity, hydrogel macromers may be synthesized without hydrolytically labile groups such as esters, and the conductive elements may be conjugated directly to the hydrogel matrix.
An implantable device comprises a plurality of electrode pairs, a sensing unit, and a pacing unit. The electrode pairs comprise a first electrode pair. The first electrode pair is configured to implant at or near a first location of a heart. The sensing unit is configured to sense electrical activity in the heart, determine that the electrical activity indicates an abnormal rhythm, determine a feature of the electrical activity, and select the first electrode pair from the electrode pairs based on the feature. The pacing unit is configured to cause, in response to the abnormal rhythm and the feature, the first electrode pair to provide a first electrical pulse at a first time.
A61N 1/368 - Heart stimulators controlled by a physiological parameter, e.g. by heart potential comprising more than one electrode co-operating with different heart regions
A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
25.
SUPPRESSING HIPPO SIGNALING IN THE STEM CELL NICHE PROMOTES SKELETAL MUSCLE REGENERATION
Embodiments of the disclosure include methods for generating skeletal muscle by targeting the Hippo pathway. In particular embodiments, an individual with a need for skeletal muscle generation is provided an effective amount of a shRNA molecule that targets the SAV1 gene. Particular shRNA sequences are disclosed.
An Example tool for implanting a pacemaker lead includes a body that includes a recess, a first electrical contact positioned within the recess, and a projection coupled to the body. In addition, the tool includes a second electrical contact positioned on the projection. The recess is configured to receive the pacemaker lead therein such that a first electrode of the pacemaker lead is to engage with the first electrical contact and a second electrode of the pacemaker lead is to engage with the second electrical contact. A rotation of the tool about a central axis of the pacemaker lead is configured to rotate the first electrical contact and the first electrode together about the central axis and to slidingly engage the second electrical contact along the second electrode.
A surgical needle is configured to detect whether a distal tip of the surgical needle perforates or ends up in an undesirable location, or detect whether the distal tip of the surgical needle has accessed a desired location. The surgical needle includes a hub and a body connected to the hub. The body has a hollow core and includes a sharp-pointed tip at a distal end. A first electrode is formed by the sharp-pointed tip of the body. At least a second electrode is provided around the body. The first and second electrodes are connected to a wired connector that can be plugged into an external sensing system. The external sensing system can monitor impedance, electrical parameters, or other parameters.
Methods for collapsing a tubular organ, such as the esophagus, involve inserting a device into the tubular organ, at least partially sealing off a section of the tubular organ, and drawing in the wall of the tubular organ by application of suction. The devices may be used to move the wall of the tubular organ away from an area undergoing treatment or therapy, such as to minimize damage to the tubular organ by application of radiofrequency energy or to limit temperature increase of the tubular organ.
A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
Systems and methods for heart stimulation in accordance with embodiments of the invention are illustrated. One embodiment includes a heart stimulation system, including a first wirelessly powered, leadless pacemaker, including a wireless power receiver tuned to a first frequency, an energy harvesting circuitry, a stimulation circuitry, and a stimulation electrode, a controller, including a wireless power signal generator, a wireless power transmitter tuned to the frequency, a processor, and a memory containing a stimulation control application, where the stimulation control application directs the processor to generate a power transfer signal using the first wireless power signal generator, and transmit the power transfer signal using the wireless power transmitter, wherein the wirelessly powered, leadless pacemaker receives the power transfer signal using the first wireless power receiver, and when receiving the power transfer signal, the energy harvesting circuitry stores power received via the wireless power receiver in at least one capacitor.
A61N 1/375 - Constructional arrangements, e.g. casings
A61N 1/368 - Heart stimulators controlled by a physiological parameter, e.g. by heart potential comprising more than one electrode co-operating with different heart regions
A61N 1/372 - Arrangements in connection with the implantation of stimulators
A composition comprises a conjugate of the formula targeting component-linker-imaging component. In an embodiment, the targeting component is a VLA-4 antagonist. In an embodiment, the targeting component is a LFA-1 antagonist. In an embodiment, the linker includes chain of 2 to 20 atoms containing any combination of —CH2—, —CH═CH—, —C(O)—, —NH—, —S—, —S(O)—, —O—, —C(O)O— or —S(O)2—; or a polyethylene glycol chain, wherein said chain of 2-20 atoms or polyethylene glycol chain are attached to the targeting and imaging components through ether, amide, sulfonamide, urea, thiourea, or triazole functional groups. In an embodiment, the imaging component is a metal chelator complexed with a metal ion or isotope thereof.
Wireless treatment of arrhythmias. At least some of the example embodiments are methods including: charging a capacitor of a first microchip device abutting heart tissue, the charging by harvesting ambient energy; charging a capacitor of a second microchip device abutting the heart tissue, the charging of the capacitor of the second microchip device by harvesting ambient energy; sending a command wirelessly from a communication device outside the rib cage to the microchip devices; applying electrical energy to the heart tissue by the first microchip device responsive to the command, the electrical energy applied from the capacitor of the first microchip device; and applying electrical energy to the heart tissue by the second microchip device responsive to the command to the second microchip device, the electrical energy applied from the capacitor of the second microchip device.
Disclosed herein is a composition comprising a plurality of liposomes having an average diameter of less than 400 nanometers, wherein the plurality of liposomes comprise: a first lipid or phospholipid; a second lipid or phospholipid which is derivatized with a polymer; and a sterically bulky excipient capable of stabilizing the liposomes; a third lipid or phospholipid derivatized with a polymer terminated with an integrin targeting component; DSPE or a fourth lipid or phospholipid derivatized with a group binding a contrast enhancing agent wherein the plurality of liposomes optionally encapsulates a payload component consisting of one or more bioactive agents.
A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
33.
ELECTRICALLY CONDUCTIVE HYDROGELS USABLE AS LEAD EXTENSIONS, APPARATUS FOR DELIVERY OF A HYDROGEL INTO THE VASCULASTURE, AND METHODS OF TREATING VENTRICULAR ARRHYTHMIA WITH ELECTRICALLY CONDUCTIVE HYDROGELS INJECTED IN THE VENOUS SYSTEM
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (USA)
Inventor
Cossgriff-Hernandez, Elizabeth
John, Mathews
Post, Allison
Wilems, Thomas
Chwatko, Malgorzata
Rook, Ashley
Razavi, Mehdi
Abstract
A conductive hydrogel precursor solution cures after injection into the vasculature of the myocardium. The vasculature acts as a mold for the hydrogel and allows for a pacing signal to be conducted across the myocardium and not at a single point like traditional pacing leads. The catheter-based delivery can accurately place the hydrogels into the myocardial veins and can fill the venous tributaries. In situ crosslinking of the hydrogel precursor solution is achieved through several mechanisms, such as redox initiation by mixing a reducing reagent and oxidizing agent after injection. Conductivity is achieved by doping in conductive polymers or other conductive elements such as ionic species, metallic nanoparticles, or graphene nanoplatelets. To ensure long-term conductivity, hydrogel macromers may be synthesized without hydrolytically labile groups such as esters, and the conductive elements may be conjugated directly to the hydrogel matrix.
A surgical needle is configured to detect whether a distal tip of the surgical needle perforates or ends up in an undesirable location, or detect whether the distal tip of the surgical needle has accessed a desired location. The surgical needle includes a hub and a body connected to the hub. The body has a hollow core and includes a sharp-pointed tip at a distal end. A first electrode is formed by the sharp-pointed tip of the body. At least a second electrode is provided around the body. The first and second electrodes are connected to a wired connector that can be plugged into an external sensing system. The external sensing system can monitor impedance, electrical parameters, or other parameters.
Systems and methods for heart stimulation in accordance with embodiments of the invention are illustrated. One embodiment includes a heart stimulation system, including a first wirelessly powered, leadless pacemaker, including a wireless power receiver tuned to a first frequency, an energy harvesting circuitry, a stimulation circuitry, and a stimulation electrode, a controller, including a wireless power signal generator, a wireless power transmitter tuned to the frequency, a processor, and a memory containing a stimulation control application, where the stimulation control application directs the processor to generate a power transfer signal using the first wireless power signal generator, and transmit the power transfer signal using the wireless power transmitter, wherein the wirelessly powered, leadless pacemaker receives the power transfer signal using the first wireless power receiver, and when receiving the power transfer signal, the energy harvesting circuitry stores power received via the wireless power receiver in at least one capacitor.
A61N 1/368 - Heart stimulators controlled by a physiological parameter, e.g. by heart potential comprising more than one electrode co-operating with different heart regions
A61N 1/372 - Arrangements in connection with the implantation of stimulators
222-; or a polyethylene glycol chain, wherein said chain of 2-20 atoms or polyethylene glycol chain are attached to the targeting and imaging components through ether, amide, sulfonamide, urea, thiourea, or triazole functional groups. In an embodiment, the imaging component is a metal chelator complexed with a metal ion or isotope thereof.
Wireless treatment of arrhythmias. At least some of the example embodiments are methods including: charging a capacitor of a first microchip device abutting heart tissue, the charging by harvesting ambient energy; charging a capacitor of a second microchip device abutting the heart tissue, the charging of the capacitor of the second microchip device by harvesting ambient energy; sending a command wirelessly from a communication device outside the rib cage to the microchip devices; applying electrical energy to the heart tissue by the first microchip device responsive to the command, the electrical energy applied from the capacitor of the first microchip device; and applying electrical energy to the heart tissue by the second microchip device responsive to the command to the second microchip device, the electrical energy applied from the capacitor of the second microchip device.
One aspect of the invention provides a trocar including: a central cylinder defining a central channel and having a distal end adapted and configured for insertion within a subject; one or more gas outlets located within the central cylinder proximate to the distal end of the trocar; and one or more liquid outlets located within the central cylinder on a proximal side of the one or more gas outlets. The one or more liquid outlets are adapted and configured to dispense a liquid when an endoscope is withdrawn from a fully extended position within the central channel of the trocar to a position proximate to the one or more liquid outlets. Distal advancement of the endoscope to a position adjacent to the one or more gas outlets removes liquid from a distal end of the endoscope.
A61B 1/12 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with cooling or rinsing arrangements
G02B 23/24 - Instruments for viewing the inside of hollow bodies, e.g. fibrescopes
A61B 90/70 - Cleaning devices specially adapted for surgical instruments
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
A61B 1/015 - Control of fluid supply or evacuation
A61M 13/00 - Insufflators for therapeutic or disinfectant purposes
A medical devices and methods related thereto are disclosed. In an embodiment, the medical device including a pump configured to be inserted within an atrium of a heart, said pump comprising an inlet and an outlet. In addition, the pump includes a flexible outflow conduit coupled to the outlet and configured to carry blood. The outflow conduit includes a radially inner surface defining a throughbore, and a radially outer surface. Further, the pump comprises a driveline configured to conduct control and power signals between the pump and an external device. The driveline extends through the outflow conduit between the radially inner surface and the radially outer surface.
A61M 60/148 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable via, into, inside, in line, branching on, or around a blood vessel in line with a blood vessel using resection or like techniques, e.g. permanent endovascular heart assist devices
A61M 60/414 - Details relating to driving for non-positive displacement blood pumps the force acting on the blood contacting member being mechanical, e.g. transmitted by a shaft or cable generated by an electromotor transmitted by a rotating cable, e.g. for blood pumps mounted on a catheter
A61M 60/135 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable via, into, inside, in line, branching on, or around a blood vessel inside a blood vessel, e.g. using grafting
Methods for collapsing a tubular organ, such as the esophagus, involve inserting a device into the tubular organ, at least partially sealing off a section of the tubular organ, and drawing in the wall of the tubular organ by application of suction. The devices may be used to move the wall of the tubular organ away from an area undergoing treatment or therapy, such as to minimize damage to the tubular organ by application of radiofrequency energy or to limit temperature increase of the tubular organ.
A61B 18/04 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
A61B 17/02 - Surgical instruments, devices or methods for holding wounds open, e.g. retractorsTractors
A61B 17/24 - Surgical instruments, devices or methods for use in the oral cavity, larynx, bronchial passages or noseTongue scrapers
A61B 17/30 - Surgical pincettes, i.e. surgical tweezers
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
A61B 1/32 - Devices for opening or enlarging the visual field, e.g. of a tube of the body
One aspect of the invention provides a biological pump including: a reservoir comprising a biomaterial, an inlet and an outlet; a first valve coupled to said inlet; and a force generator coupled to said reservoir and configured to compress said reservoir. Another aspect of the invention provides a method of assisting a patient with a Fontan circuit. The method includes implanting a biological pump as described herein into a chest cavity of a patient. Another aspect of the invention provides a method of assisting a patient with a Fontan circuit. The method includes implanting the biological pump as described herein within a Fontan circuit of said patient.
Disclosed herein is a composition comprising a plurality of liposomes having an average diameter of less than 400 nanometers, wherein the plurality of liposomes comprise: a first lipid or phospholipid; a second lipid or phospholipid which is derivatized with a polymer; and a sterically bulky excipient capable of stabilizing the liposomes; a third lipid or phospholipid derivatized with a polymer terminated with an integrin targeting component; DSPE or a fourth lipid or phospholipid derivatized with a group binding a contrast enhancing agent wherein the plurality of liposomes optionally encapsulates a payload component consisting of one or more bioactive agents.
Wireless treatment of arrhythmias. At least some of the example embodiments are methods including: charging a capacitor of a first microchip device abutting heart tissue, the charging by harvesting ambient energy; charging a capacitor of a second microchip device abutting the heart tissue, the charging of the capacitor of the second microchip device by harvesting ambient energy; sending a command wirelessly from a communication device outside the rib cage to the microchip devices; applying electrical energy to the heart tissue by the first microchip device responsive to the command, the electrical energy applied from the capacitor of the first microchip device; and applying electrical energy to the heart tissue by the second microchip device responsive to the command to the second microchip device, the electrical energy applied from the capacitor of the second microchip device.
A magnet assisted surgical device, system, and method employs magnetic sections, catheters, and guidewires to modify tubular stentgrafts in-situ. One example application provides a more reliable way for surgeons to modify stentgrafts insitu to allow blood flow to continue to branching blood vessels that would otherwise be blocked by the stentgraft itself. One such method includes placing a tip section of the device in the desired location, deploying a stentgraft, placing a magnetic device inside the stentgraft, connecting the magnetic device to the tip section, and excising the portion of the stentgraft held between the magnet and the tip section.
Embodiments of the disclosure include methods and compositions for the renewal of cardiomyocytes by targeting the Hippo pathway. In particular embodiments, an individual with a need for cardiomyocyte renewal is provided an effective amount of a shRNA molecule that targets the Sav1 gene. Particular shRNA sequences are disclosed.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
One aspect of the invention provides a trocar including: a central cylinder defining a central channel and having a distal end adapted and configured for insertion within a subject; one or more gas outlets located within the central cylinder proximate to the distal end of the trocar; and one or more liquid outlets located within the central cylinder on a proximal side of the one or more gas outlets. The one or more liquid outlets are adapted and configured to dispense a liquid when an endoscope is withdrawn from a fully extended position within the central channel of the trocar to a position proximate to the one or more liquid outlets. Distal advancement of the endoscope to a position adjacent to the one or more gas outlets removes liquid from a distal end of the endoscope.
Methods for collapsing a tubular organ, such as the esophagus, involve inserting a device into the tubular organ, at least partially sealing off a section of the tubular organ, and drawing in the wall of the tubular organ by application of suction. The devices may be used to move the wall of the tubular organ away from an area undergoing treatment or therapy, such as to minimize damage to the tubular organ by application of radiofrequency energy or to limit temperature increase of the tubular organ.
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
A61B 1/32 - Devices for opening or enlarging the visual field, e.g. of a tube of the body
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A system, device and method for insertion of a penetrating member into tissue is disclosed, which may be handheld and automated. A detector obtains data regarding subdermal locations of tissue structures, including cavities such as blood vessels. A processor calculates the distance between a preselected target point below the tissue surface, such as within a blood vessel, and the tissue surface, and adjustment data for vertical, angular and extension adjustment of the penetrating member. Vertical, angular and extension actuators carry out the adjustments in real-time as calculated and directed by the processor. Changes in the location of the target point result in automatic recalculation and adjustment by the processor and various actuators. A vibrational actuator induces vibration to the penetrating member during insertion, overcome tissue deformation and vein rolling. A guidewire may be inserted through or by the device, for dilator and catheter insertion once the penetrating member is removed.
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Educational services, namely, arranging and conducting educational conferences in the field of cardiovascular medicine and other medicine; development and dissemination of printed educational materials of others in the field of cardiovascular medicine and other medicine, conducting educational conferences, courses and symposia, and distributing course materials in connection therewith, in the field of cardiovascular medicine; entertainment services in the nature of competitions in the field of athletics, namely, arranging and conducting athletic competitions Providing medical testing services in the field of heart disease research and disease classification; medical and scientific research and medical laboratories in the field of cardiovascular medicine; design and testing for new product development and of new products for others; medical laboratory services; product development and product development consultation; product safety testing; research and development of new products for others; technical medical and scientific research in the field of cardiovascular medicine Medical services; medical testing for diagnostic or treatment purposes; technical medical consultation in the field of cardiovascular medicine
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
educational services, namely, arranging and conducting educational conferences in the field of cardiovascular medicine and other medicine; development and dissemination of printed educational materials of others in the field of cardiovascular medicine and other medicine, conducting educational conferences, courses and symposia, and distributing course materials in connection therewith, in the field of cardiovascular medicine; entertainment services in the nature of competitions in the field of athletics, namely, arranging and conducting athletic competitions Providing medical testing services in the field of heart disease research and disease classification; medical and scientific research and medical laboratories in the field of cardiovascular medicine; design and testing for new product development and of new products for others, medical laboratory services; product development and product development consultation; product safety testing; research and development of new products for others; technical medical and scientific research in the field of cardiovascular medicine Medical services; medical testing for diagnostic or treatment purposes; technical medical consultation in the field of cardiovascular medicine
51.
Agonists that enhance binding of integrin-expressing cells to integrin receptors
A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.
C07D 333/20 - Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
C07D 333/24 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07C 229/34 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
C07C 271/22 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
C07C 311/08 - Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
C07C 271/20 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 275/02 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
C07D 213/64 - One oxygen atom attached in position 2 or 6
C07D 317/60 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
52.
METHOD AND DEVICE FOR DETECTION OF ARRHYTHMIAS AND MYOCARDIAL INJURY
Herein disclosed is a method of detecting and identifying the source of abnormal electrical currents in the heart to assist in ablating these currents, comprising the use of contact or non-contact temperature measurement devices. In an embodiment, source of abnormal electrical activity of the heart and its attached arteries and veins show different temperature patterns from normal segments. In an embodiment, the method further comprises analyzing the temperature of the chamber of interest, and determining regions of low or high temperature by extension metabolic activity. In an embodiment, the method comprises measuring myocardial temperature comprising placing an array of thermocouples imbedded on a basket in the cardiac chamber. In an embodiment, the thermocouples are placed in contact with the myocardial tissue.
Herein disclosed is a method of detecting and identifying the source of abnormal electrical currents in the heart to assist in ablating these currents, comprising the use of contact or non-contact temperature measurement devices. In an embodiment, source of abnormal electrical activity of the heart and its attached arteries and veins show different temperature patterns from normal segments. In an embodiment, the method further comprises analyzing the temperature of the chamber of interest, and determining regions of low or high temperature by extension metabolic activity. In an embodiment, the method comprises measuring myocardial temperature comprising placing an array of thermocouples imbedded on a basket in the cardiac chamber. In an embodiment, the thermocouples are placed in contact with the myocardial tissue.
The present invention is directed to methods and compositions that provide therapy for at least one medical condition that directly or indirectly affects cardiac muscle cells (also known as cardiomyocytes) in a mammalian individual, including humans, dogs, cats, horse pigs, and so forth. The medical condition may be of any kind, including a cardiac condition such as heart failure, cardiomyopathy, myocardial infarction, and so forth. The medical condition may have a cardiac condition as its primary symptom or cause or it may be a secondary symptom or cause. The individual may be male or female and may be of any age.
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
A magnet assisted surgical device, system, and method employs magnetic sections, catheters, and guidewires to modify tubular stentgrafts in-situ. One example application provides a more reliable way for surgeons to modify stentgrafts in-situ to allow blood flow to continue to branching blood vessels that would otherwise be blocked by the stentgraft itself. One such method includes placing a tip section of the device in the desired location, deploying a stentgraft, placing a magnetic device inside the stentgraft, connecting the magnetic device to the tip section, and excising the portion of the stentgraft held between the magnet and the tip section.
A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.
C07D 333/20 - Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
C07D 275/02 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07C 271/20 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
C07C 311/08 - Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
C07D 213/64 - One oxygen atom attached in position 2 or 6
C07D 317/60 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
C07C 229/34 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
C07C 271/22 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
C07D 333/24 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
57.
METHODS OF USING CYCLOOXYGENASE-PROSTACYCLIN SYNTHASE FUSION GENE
An effective amount of a composition comprising (i) a plasmid having a cyclooxygenase-prostacyclin synthase fusion gene, and (ii) a carrier fluid for use in treating an individual having a vascular disease or at risk of developing a vascular disease. A composition comprising a carrier fluid; and a DNA sequence encoding for a triple catalytic enzyme, a cDNA sequence encoding for a triple catalytic enzyme, a plasmid comprising a DNA sequence encoding for a triple catalytic enzyme, a fusion gene encoding for a triple catalytic enzyme, a cyclooxygenase-prostacyclin synthase fusion gene, or combinations thereof, for use in treating an individual having a vascular disease or at risk of developing a vascular disease.
An effective amount of a composition comprising a stem cell, a stem cell engraftment enhancer, and a carrier fluid, for use in the treatment of an individual having a disease or at risk of developing a disease, wherein the disease is a vascular-associated disease and/or a muscular disease. A composition comprising PGI2-overexpressing human mesenchymal stem cells (PGI2-hMSCs), and a carrier fluid; wherein an effective amount of the composition is administered via a single treatment stream as an intramuscular injection to an individual having a disease or at risk of developing a disease, wherein the disease is a vascular-associated disease and/or a muscular disease, and wherein stem cell engraftment is enhanced in said individual by greater than about 200%, when compared to stem cell engraftment in an individual treated with a composition lacking the stem cell engraftment enhancer.
A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.
C07D 333/20 - Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
C07C 271/22 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
C07C 229/34 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
C07D 333/24 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 317/60 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07C 311/08 - Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
C07C 271/20 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
C07D 275/02 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 213/64 - One oxygen atom attached in position 2 or 6
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
Systems and methods for deploying and securing conductive materials to a region of tissue may utilize a catheter. The catheter may provide a tip with one or more detachable sections or may provide an adjustable opening. A lumen of the catheter may provide a conductive material, such as a filament, fiber, network or patch of carbon nanotubes (CNTs) or carbon nanofibers (CNFs). In some embodiments, the conductive materials may be coupled to securing mechanisms, such as screws, clips, anchors, alligator clips, or anchors with barbs, which can be actuated to attach the conductive materials to desired regions of tissue. In some embodiments, the catheter may provide a needle tip that allows the conductive material to be embedded into desired regions of tissue by inserting the needle into the tissue.
The present invention is directed to methods and compositions that provide therapy for at least one medical condition that directly or indirectly affects cardiac muscle cells (also known as cardiomyocytes) in a mammalian individual, including humans, dogs, cats, horse pigs, and so forth. The medical condition may be of any kind, including a cardiac condition such as heart failure, cardiomyopathy, myocardial infarction, and so forth. The medical condition may have a cardiac condition as its primary symptom or cause or it may be a secondary symptom or cause. The individual may be male or female and may be of any age.
A system for aiding in the proper placement of an endotracheal tube in the trachea of a patent includes an endotracheal tube having a proximal region and a distal region. At least one electrode is included on the distal region to provide an electrical stimulation signal to patient tissue. The system includes a control unit coupled to the electrode and configured to differentiate proper placement of the endotracheal tube in the patient's trachea from improper placement of the endotracheal tube in the patient's esophagus based on a sensed response to the electrical stimulation provided by the electrode.
Some embodiments of the present disclosure pertain to methods of improving electrical conduction across an impaired region of a tissue (e.g., myocardial tissue) by applying an electrically conductive material (e.g., carbon nanotube fibers) across the impaired region. The electrically conductive materials can become associated with non-impaired regions of the tissue on opposite sides of the impaired region by suturing. Such methods can also be utilized to treat or prevent cardiac arrhythmia in a subject (e.g., ventricular arrhythmia). Additional embodiments of the present disclosure pertain to electrical wirings that include carbon nanotubes, such as carbon nanotube fibers. Such electrical wirings can be used to transmit electrical signals to a tissue or sense electrical signals from the tissue. In some embodiments, the present disclosure also pertains to suture threads that include carbon nanotubes, such as carbon nanotube fibers.
Methods of making anionic liposomal FABP4 siRNA, and an anionic liposomal atherosclerosis related siRNA delivery system, for targeting atherosclerosis. A method of making an anionic liposomal siRNA comprising: mixing a lipid-A and a lipid-B to form a lipid mixture comprising lipid-A and lipid-B; and mixing: (i) the lipid mixture, (ii) an siRNA, and (iii) a solvent to form a liposome. In another embodiment the siRNA further comprises a fluorescent tag. In some embodiments of the method of making an anionic liposomal siRNA, lipid-A comprises DMPG, in other embodiment, lipid-S comprises DMPC.
A method for modulating cell differentiation capabilities using heterologous gene expression. Some embodiments of the invention relate to a method for inducing a cardiac progenitor cell by delivering a reprogramming factor to the cell, wherein the reprogramming factor comprises ETS2 or a combination of ETS2 and Mesp1.
An embodiment of a system for aiding in the proper placement of an endotracheal tube in the trachea of a patent comprises an endotracheal tube having a proximal region and a distal region, the distal region including an electrode. In addition, the endotracheal tube comprises a control unit coupled to the electrode to differentiate proper placement of the endotracheal tube in the patient's trachea from improper placement of the endotracheal tube in the patient's esophagus based on a sensed electrical signal from the electrode.
An introducer comprise a sheath for introducing a catheter into a blood vessel, a plurality of electrodes on the sheath, and an impedance assessment unit provided on the sheath and connected to the electrodes. The impedance assessment unit fixes one of a current or voltage across a first pair of the electrodes and measures the other of the current or voltage across a second pair of electrodes.
A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters
A61M 25/06 - Body-piercing guide needles or the like
A61M 25/088 - Introducing, guiding, advancing, emplacing or holding catheters using an additional catheter, e.g. to reach relatively inaccessible places
68.
Agonists that enhance binding of integrin-expressing cells to integrin receptors
A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.
C07D 333/20 - Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 275/02 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
C07C 271/20 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
C07C 311/08 - Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
C07D 213/64 - One oxygen atom attached in position 2 or 6
C07D 317/60 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
C07C 229/34 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
C07C 271/22 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
C07D 333/24 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
69.
IDENTIFICATION OF SPECIFIC APOLIPOPROTEIN EPITOPES ON CIRCULATING ATHEROGENIC LOW-DENSITY LIPOPROTEIN
An isolated peptidic fragment of apolipoprotein E comprises at least 3 contiguous amino acids, including glycosylated threonine 194, threonine 289, serine 94, or serine 76 of SEQ ID NO.: 1, or any combination of those. An antibody capable of binding to the isolated peptidic fragment. A method of detecting a naturally-occurring circulating atherogenic low-density lipoprotein in a plasma sample from an individual, comprising qualitatively and/or quantitatively detecting in a low-density lipoprotein that binds to the antibody. A method of assessing an individual's risk of ischemic heart disease and/or atherosclerosis comprises quantifying in a plasma sample from the individual an amount of apolipoprotein E comprising glycosylated threonine 194, threonine 289, serine 94 or serine 76 of SEQ ID NO.: 1, or any combination of those.
A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
In an embodiment a sheath allows one to simultaneously ablate tissue, using a catheter located in the sheath, and remove fluid from a patient's pericardial space, via the same sheath, all without withdrawing the ablation catheter from the sheath. Applying pressure (positive or negative) to fenestrations in the sheath may allow one to withdraw fluid from the space, navigate the sheath within the space, and/or adhere the sheath to tissue in the space. Other embodiments are described herein.
A61B 18/18 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
A61M 25/06 - Body-piercing guide needles or the like
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A61B 18/02 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
72.
Device, system, and method for a stress sensing medical needle
In an embodiment, an apparatus comprises a needle (e.g., hypodermic needle or trocar) and sensor (e.g., fiber Braggs grating sensor) coupled to a system to determine (e.g., in real time) stress and/or vibrations encountered by the needle. Consequently, various embodiments may (a) help identify nearby vessels, (b) determine whether the needle penetrated a hollow body structure, and (c) accurately guide needles towards a target structure (e.g., vessel). Other embodiments are described herein.
A61B 5/05 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G01L 1/24 - Measuring force or stress, in general by measuring variations of optical properties of material when it is stressed, e.g. by photoelastic stress analysis
73.
ETS2 and MESP1 generate cardiac progenitors from fibroblasts
A method for modulating cell differentiation capabilities using heterologous gene expression. Some embodiments of the invention relate to a method for inducing a cardiac progenitor cell by delivering a reprogramming factor to the cell, wherein the reprogramming factor comprises ETS2 or a combination of ETS2 and Mesp1.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
74.
ETS2 AND MESP1 GENERATE CARDIAC PROGENITORS FROM FIBROBLASTS
A method for modulating cell differentiation capabilities using heterologous gene expression. Some embodiments of the invention relate to a method for inducing a cardiac progenitor cell by delivering a reprogramming factor to the cell, wherein the reprogramming factor comprises ETS2 or a combination of ETS2 and Mespl.
The temperature of a patient is a significant predictor of death in heart failure patients. Temperature provides a window into the physiology of the patient's underlying condition and may be used as an early marker for CHF exacerbations. The patient's temperature is taken to form a time series of temperature values. In accordance with some embodiments, the time series of temperature values is converted to the frequency domain by, for example, a discrete Fourier Transform. The frequency domain representation then is analyzed for a marker indicative of the worsening condition of the patient. In accordance with other embodiments, the patient's time series of temperature values is analyzed for a marker using, for example, Cosinor analysis. In yet other embodiments, both the time and frequency domain temperature data is analyzed for markers of the patient's worsening medical condition.
A vascular access device comprises a bridge having first and second bores therethrough, a dilator in the first bore, and a needle guide in the second bore. The second bore is at an angle with respect to the first bore such that the needle guide is at the angle with respect to the dilator. The device is useful, for example to achieve dual site entrance to a blood vessel.
A medical device comprises a pump adapted to fit within an atrium of a heart, said pump comprising an inlet and an outlet. The device further comprises a flexible outflow conduit coupled to said outlet. A method of assisting ventricular function of a heart of a patient comprises: a) inserting a continuous flow pump having an inlet and an outlet into the heart via a subclavian or jugular vein; b) attaching the outlet of the continuous flow pump to an atrial septum, wherein the inlet of the continuous flow pump is directed into a heart atrium; c) attaching the distal end of the outflow conduit to an artery; and d) operating the pump at a volumetric rate ranging from about 2 L/min to about 3 L/min.
A system and method for joining an end of a tubular prosthesis to the wall of a vessel wherein an anvil is inserted into the vessel through an opening in the vessel wall produced by a cutting surface on the anvil. The anvil is operated via an anvil handle which may extend through the tubular prosthesis. The tubular prosthesis is guided to the opening in the vessel wall whereupon jaws clamp the prosthesis around the anvil. Staples mounted on the jaws engage the anvil and are bent to thereby staple the end of the tubular prosthesis to the vessel wall. A cutting edge may be mounted to the anvil and utilized to create an enlarged hole to permit blood flow into the tubular prosthesis and to permit removal of the anvil from the vessel.
A61B 17/11 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for performing anastomosisButtons for anastomosis
A61B 17/115 - Staplers for performing anastomosis, e.g. in a single operation
Methods and devices for prevention of a pneumothorax during vascular access are disclosed herein. The methods utilize a device having a detachable distal portion which serves to block the passageway created after a vascular access procedure. The device may include retention means to secure the device in the passageway. In addition, the methods may make use of tissue adhesives or glues to further ensure sealing of the passage. Furthermore, the disclosed methods and devices may be used to block perforations of blood vessels created during vascular access.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61B 19/00 - Instruments, implements or accessories for surgery or diagnosis not covered by any of the groups A61B 1/00-A61B 18/00, e.g. for stereotaxis, sterile operation, luxation treatment, wound edge protectors(protective face masks A41D 13/11; surgeons' or patients' gowns or dresses A41D 13/12; devices for carrying-off, for treatment of, or for carrying-over, body liquids A61M 1/00)
41 - Education, entertainment, sporting and cultural services
Goods & Services
educational services, namely, arranging and conducting educational conferences, development and dissemination of educational materials in the field of cardiovascular medicine and other medicine, conducting conferences, courses and symposia, distributing course materials therewith, in the field of cardiovascular medicine and entertainment services in the nature of competitions in the field of athletics, namely, arranging sponsoring and conducting athletic competitions
41 - Education, entertainment, sporting and cultural services
Goods & Services
educational services, namely, arranging and conducting educational conferences, development and dissemination of educational materials in the field of cardiovascular medicine and other medicine, conducting conferences, courses and symposia, distributing course materials therewith, in the field of cardiovascular medicine and entertainment services in the nature of competitions in the field of athletics, namely, arranging sponsoring and conducting athletic competitions
42 - Scientific, technological and industrial services, research and design
Goods & Services
health care services, namely, medical clinic services, medical services, medical testing, physician services, medical and scientific research and laboratory medicine in the field of cardiovascular medicine, design and testing for new product development/new products for others, medical laboratory services, product development and product development consultation, product safety testing, research and development of new products for others, technical consultation and research in the field of cardiovascular medicine
42 - Scientific, technological and industrial services, research and design
Goods & Services
health care services, namely, medical clinic services, medical services, medical testing, physician services, medical and scientific research and laboratory medicine in the field of cardiovascular medicine, design and testing for new product development/new products for others, medical laboratory services, product development and product development consultation, product safety testing, research and development of new products for others, technical consultation and research in the field of cardiovascular medicine
41 - Education, entertainment, sporting and cultural services
Goods & Services
educational services, namely, arranging and conducting educational conferences, development and dissemination of educational materials in the field of cardiovascular medicine and other medicine, conducting conferences, courses and symposia, distributing course materials therewith, in the field of cardiovascular medicine and entertainment services in the nature of competitions in the field of athletics, namely, arranging sponsoring and conducting athletic competitions
09 - Scientific and electric apparatus and instruments
Goods & Services
audio tapes featuring cardiology and/or cardiovascular medicine and research; and video tapes featuring cardiology and/or cardiovascular medicine and research
41 - Education, entertainment, sporting and cultural services
Goods & Services
entertainment services in the nature of competitions in the field of athletics, namely, arranging, sponsoring and conducting athletic competitions; and educational services, namely, arranging and conducting educational conferences; development and dissemination of educational materials in the field of cardiovascular medicine and other medicine; conducting conferences, courses and symposiums and distributing course materials in connection therewith, in the field of cardiovascular medicine
42 - Scientific, technological and industrial services, research and design
Goods & Services
health care services, namely, medical clinic services, medical services, medical testing, physician services, medical and scientific research and laboratory medicine in the field of cardiovascular medicine, design and testing for new product development/new products for others, medical laboratory services, product development and product development consultation, product safety testing, research and development of new products for others, technical consultation and research in the field of cardiovascular medicine
42 - Scientific, technological and industrial services, research and design
Goods & Services
health care services, namely, medical clinic services, medical services, medical testing, physician services, medical and scientific research and laboratory medicine in the field of cardiovascular medicine, design and testing for new product development/new products for others, medical laboratory services, product development and product development consultation, product safety testing, research and development of new products for others, technical consultation and research in the field of cardiovascular medicine
92.
NOVEL COMPOSITIONS AND METHODS FOR IMMUNOTHERAPIES COMPRISING SMALL MOLECULE INTEGRIN RECEPTOR-LIGAND AGONIST ADJUVANTS
Small molecule integrin ligand mimetics facilitate integrin-ligand interactions, which maybe used to prepare vaccines, adoptive cell therapies, immunotherapies for cancer, and a variety of other conditions. As integrin mediated cell-cell interactions are critical to antigen presentation and effector cell killing, increasing the efficiency of integrin receptor-ligand interactions will stabilize the immune synapse and improve effector functions. Compositions and methods including the mimetics enhance: (1) the priming of vaccines (including, but not limited to, cancer vaccines); (2) cytolytic activity of adoptive cell therapies (including, but not limited to ?d?-cells, CTLs, NK, iNKT); (3) immunotherapies (including, but not limited to, negative checkpoint blockage strategies such as anti- CTLA-4 and anti-PD-1); and (4) biologic therapies (including, but not limited, to trastuzumab and rituxamab), whereby the mechanism-of-action includes antibody dependent cellular cytotoxicity (ADCC).
A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of .alpha.4.beta.1, .alpha.5.beta.1, .alpha.4.beta.7, .alpha.v.beta.3 and .alpha.L.beta.2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal. (see formula I)
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/4436 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
C07D 333/20 - Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
94.
AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS
A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of .alpha.4.beta.1, .alpha.5.beta.1, .alpha.4.beta.7, .alpha.v.beta.3 and .alpha.L.beta.2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.(see formula I)
A system, device and method for insertion of a penetrating member into tissue is disclosed, which may be handheld and automated. A detector obtains data regarding subdermal locations of tissue structures, including cavities such as blood vessels. A processor calculates the distance between a preselected target point below the tissue surface, such as within a blood vessel, and the tissue surface, and adjustment data for vertical, angular and extension adjustment of the penetrating member. Vertical, angular and extension actuators carry out the adjustments in real-time as calculated and directed by the processor. Changes in the location of the target point result in automatic recalculation and adjustment by the processor and various actuators. A vibrational actuator induces vibration to the penetrating member during insertion, overcome tissue deformation and vein rolling. A guidewire may be inserted through or by the device, for dilator and catheter insertion once the penetrating member is removed.
Disclosed herein is a composition comprising a plurality of liposomes having an average diameter of less than 400 nanometers, wherein the plurality of liposomes comprise: a first lipid or phospholipid; a second lipid or phospholipid which is derivatized with a polymer; and a sterically bulky excipient capable of stabilizing the liposomes; a third lipid or phospholipid derivatized with a polymer terminated with an integrin targeting component; DSPE or a fourth lipid or phospholipid derivatized with a group binding a contrast enhancing agent wherein the plurality of liposomes optionally encapsulates a payload component consisting of one or more bioactive agents.
A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
C08G 65/335 - Polymers modified by chemical after-treatment with organic compounds containing phosphorus
A surgical needle is configured to detect whether a distal tip of the surgical needle perforates or ends up in an undesirable location, or detect whether the distal tip of the surgical needle has accessed a desired location. The surgical needle includes a hub and a body connected to the hub. The body has a hollow core and includes a sharp-pointed tip at a distal end. A first electrode is formed by the sharp-pointed tip of the body. At least a second electrode is provided around the body. The first and second electrodes are connected to a wired connector that can be plugged into an external sensing system. The external sensing system can monitor impedance, electrical parameters, or other parameters.
A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of a4ß1, a5ß1, a4ß7, avß3 and aLß2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Disclosed herein, in some aspects, are endotracheal stimulation platforms, systems, and methods of their use for pacing the phrenic nerves, right and/or left phrenic nerves, of a subject. In some embodiments, one or more pairs of electrodes are provided through an ET tube to contact a portion of a tracheal wall, or trachea, so as to enable phrenic nerve pacing. In some cases, the one or more pairs of electrodes are configured to send electrical pulses that stimulate the phrenic nerve, thereby helping promote contraction and relaxation of the diaphragm muscle.
N,N-disubstituted arylamine compounds and to their use as integrin agonists for enhancing binding of integrin-expressing cells to integrin-binding ligands or receptors.
C07D 213/89 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
C07D 263/48 - Nitrogen atoms not forming part of a nitro radical
C07D 277/42 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
C07D 279/08 - 1,3-ThiazinesHydrogenated 1,3-thiazines condensed with carbocyclic rings or ring systems
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
